Immunex has initiated legal proceedings against French pharma major Sanofi (Euronext: SAN) and US biotech Regeneron Pharmaceuticals (Nasdaq: REGN).
The Amgen (Nasdaq: AMGN) subsidiary filed the suit in a Californian court, alleging that the companies’ atopic dermatitis drug Dupixent (dupilumab) infringes one of its patents related to a failed asthma treatment.
The case adds to an increasingly fractious web of litigation between the companies, which since 2014 have been feuding over cholesterol drugs Praluent (alirocumab) and Repatha (evolocumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze